miR17 - 92家族在消化系统癌症患者中的预后价值：一项系统评价和荟萃分析
Prognostic value of miR17-92 family in patients with digestive system cancers: a systematic review and meta-analysis.
作者信息
Zhang Xiaoyun, Zhang Shijie, He Qin, Gao Xiaojuan, Yang Lijun, Xu Peipei, Zhao Rui, Wang Qian, Zhang Lina, Zhao Panpan
机构信息
Department of Clinical Laboratory, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China,
Department of Clinical Laboratory, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China.
出版信息
Cancer Manag Res. 2019 Jan 22;11:1043-1058. doi: 10.2147/CMAR.S189113. eCollection 2019.
The miR17-92 family is found to be aberrantly expressed and associated with clinicopathological characteristics in patients with various cancers, including digestive system cancers. However, its prognostic value is not yet established. Therefore, we performed a systematic review and meta-analysis to investigate the association between miR17-92-family expression and clinical outcomes in digestive system cancers. We searched the PubMed, Web of Science, Embase, and CNKI (Chinese) databases to retrieve eligible studies up to June 30, 2018. Prognostic data and clinicopathological features of overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) were extracted to evaluate correlations of the miR17-92 family with digestive system cancers. We used HRs to assess association between miR17-92-family expression and cancers prognosis. A total of 30 qualifying studies involving 4,056 subjects were included in this meta-analysis. Our results indicated that expression levels of miR17-92 can predict poor OS (HR 1.21, 95% CI 1.03-1.39; =0). However, there was no relationship between the miR17-92 family and DFS (HR 0.86, 95% CI 0.6-1.11; =0.170) or PFS (HR 1.37, 95% CI 0.83-1.91; =0). Moreover, miR17-92 was related to TNM stage (III/IV vs I/II, HR 1.37, 95% CI 1.17-1.570; =0.012), but there was no relationship between miR17-92 and metastasis (HR 1.64, 95% CI 1.34-1.95; =0.491) or tumor size (≥5 cm vs <5 cm, HR 1.29, 95% CI 1.09-1.49; =0.586). Subgroup analysis showed that miR17-92 expression was associated with poor OS among the Chinese subgroup (HR 1.28, 95% CI 1.08-1.48; =0) and tissue samples (HR 1.12, 95% CI 0.93-1.31; =0), while there was no association with other characteristics. Our results indicated that miR17-92 expression is significantly associated with poor survival in patients with digestive system cancers, suggesting that miR17-92 may be a promising prognostic marker to monitor prognosis and progression of cancers.
研究发现，miR17 - 92家族在包括消化系统癌症在内的各种癌症患者中表达异常，并与临床病理特征相关。然而，其预后价值尚未明确。因此，我们进行了一项系统评价和荟萃分析，以研究miR17 - 92家族表达与消化系统癌症临床结局之间的关联。我们检索了PubMed、Web of Science、Embase和中国知网（中文）数据库，以检索截至2018年6月30日的符合条件的研究。提取总生存期（OS）、无病生存期（DFS）和无进展生存期（PFS）的预后数据及临床病理特征，以评估miR17 - 92家族与消化系统癌症的相关性。我们使用风险比（HRs）评估miR17 - 92家族表达与癌症预后之间的关联。本荟萃分析共纳入30项符合条件的研究，涉及4056名受试者。我们的结果表明，miR17 - 92的表达水平可预测较差的总生存期（HR 1.21，95%置信区间1.03 - 1.39；P = 0）。然而，miR17 - 92家族与无病生存期（HR 0.86，95%置信区间0.6 - 1.11；P = 0.170）或无进展生存期（HR 1.37，95%置信区间0.83 - 1.91；P = 0）之间无相关性。此外，miR17 - 92与TNM分期相关（III/IV期与I/II期相比，HR 1.37，95%置信区间1.17 - 1.570；P = 0.012），但miR17 - 92与转移（HR 1.64，95%置信区间1.34 - 1.95；P = 0.491）或肿瘤大小（≥5 cm与<5 cm相比，HR 1.29，95%置信区间1.09 - 1.49；P = 0.586）之间无相关性。亚组分析表明，在中国亚组（HR 1.28，95%置信区间1.08 - 1.48；P = 0）和组织样本（HR 1.12，95%置信区间0.93 - 1.31；P = 0）中，miR17 - 92表达与较差的总生存期相关，而与其他特征无相关性。我们的结果表明，miR17 - 92表达与消化系统癌症患者的不良生存显著相关，提示miR17 - 92可能是监测癌症预后和进展的一个有前景的预后标志物。
Zotero 插件